People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Innocrin Pharmaceuticals Holdings, LLC | — | Pharmaceuticals | Series B | $42.1M | $204.0M | 2017 |
Charles Edward Osborne at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles Edward Osborne on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| S Edward Torres | 1 | 8 |
| William Moore | 1 | 7 |
| FRED ESHELMAN | 1 | 5 |
| Richard Kent | 1 | 5 |
| James Rosen | 1 | 4 |
| Steven Weinstein | 1 | 4 |
| Douglas Reed | 1 | 4 |
| Andrew Edward Von Eschenbach | 1 | 2 |
| Fred Edward Eshelman | 1 | 1 |
| Kristopher Edward Wood | 1 | 1 |
| Thomas Edward Laundon | 1 | 1 |
| Robert Edward Schotzinger | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.